Written by Ashleigh C. Hamilton
Published in Vol 2 Issue 2, 2022
This study investigated the clinical and pathological profiles of germinal center (GC)-derived diffuse large B-cell lymphomas (DLBCL) with abnormal MUM1 co-expression, focusing on comparisons between pediatric and adult patients. A total of 32 cases showing aberrant MUM1 expression were analyzed, comprising 12 pediatric and 20 adult patients. The lymphomas showed a wide age distribution, affected various anatomical locations, and presented with complex histological and clinical features. Pediatr
Read More
Written by Kerry J. Savage
Published in Vol 2 Issue 2, 2022
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon form of Hodgkin lymphoma (HL) that is characterized by its distinct morphology, typically affects older individuals, and has a lower incidence of mediastinal involvement. It is also associated with a higher relapse rate and a better prognosis compared to classical Hodgkin lymphoma (CHL). Unlike CHL, the tumor cells in NLPHL, known as LP cells, usually retain a B cell phenotype and do not express CD30. Due to the rarity of thi
Read More
Written by Prita Pradhan
Published in Vol 2 Issue 2, 2022
Dedifferentiated liposarcoma (DDL) with unusual forms of tissue differentiation is rarely seen and varies in presentation. These tumors often arise in the retroperitoneal area, where they tend to grow silently to a large size, appear late, and have a poor prognosis. We describe a rare case of an elderly male who initially presented with what appeared to be an inguinal hernia. Further evaluation revealed a large abdominal mass. CT imaging showed that the tumor occupied most of the left side of th
Read More
Written by Francescamaria Donati
Published in Vol 2 Issue 2, 2022
The solid pseudopapillary tumor of the pancreas (SPT), also known as a Frantz tumor, was first identified in 1959 by its namesake. This uncommon pancreatic tumor, previously known as papillary epithelial neoplasm, low-grade papillary neoplasm, or solid and papillary neoplasm, predominantly affects younger individuals, with a notable female predominance. Its cellular origin remains uncertain, with potential links to acinar, endocrine, ductal, or progenitor cells. Characterized by a favorable prog
Read More
Written by Marcela RosasNexticapa
Published in Vol 2 Issue 2, 2022
Prostate cancer remains one of the most common causes of cancer-related mortality among men globally. Evidence indicates that ribosomal S6 p90 kinases (RSK 1–4), a group of highly conserved serine/threonine kinases, may be associated with elevated prostate cancer levels. This study aimed to theoretically evaluate the interaction between various quinolone derivatives (compounds 1–19) and RSK-4, utilizing the structure of the 6rv2 protein and the known RSK-14 inhibitor, LJH685, through molecular d
Read More
Written by Ana Tarhan
Published in Vol 2 Issue 2, 2022
Chemotherapy plays a central role in the management of advanced-stage gastric cancer, helping to extend survival and improve quality of life. However, there is still no consensus on whether doublet or triplet chemotherapy regimens should be used as the standard treatment for these patients. This retrospective study examines first-line chemotherapy options for metastatic gastric cancer at five medical centers in Turkey. The inclusion criteria required patients to have metastatic gastric adenocarc
Read More
Written by Gaurav Singh
Published in Vol 2 Issue 2, 2022
Early diagnosis and prompt treatment of pediatric acute leukemia are crucial for improving survival outcomes. This study aimed to investigate the factors contributing to delays in diagnosing acute leukemia in children. A prospective observational study was conducted at a specialized hospital in Northern India, enrolling 100 children aged 0-12 years over 18 months. A combination of quantitative data and qualitative interviews was used to gather insights. Caregivers completed a standardized questi
Read More
Written by Siti Nur Haliza
Published in Vol 2 Issue 2, 2022
Trastuzumab deruxtecan (T-DXd) offers substantial benefits for individuals with HER2-positive or HER2-low advanced breast cancer (ABC), though it carries a distinctive adverse event profile, notably interstitial lung disease (ILD). A retrospective observational cohort analysis was performed to assess the safety and effectiveness of T-DXd in patients with HER2-positive/low ABC managed at the European Institute of Oncology between December 2019 and April 2025. Key outcomes encompassed the cumulati
Read More
Written by Sofia Maria Costa
Published in Vol 2 Issue 2, 2022
Perineural invasion (PNI) represents a clinically significant and independent indicator of metastatic risk in prostate cancer (PCa). Although gastrin-releasing peptide receptor (GRPR)–directed imaging and therapeutic approaches are currently under clinical evaluation, the contribution of GRPR signaling to PNI in PCa has not been fully elucidated. In this study, we identify Family With Sequence Similarity 135 Member A (FAM135A) as a key GRPR-activated regulator driving PNI in PCa. Transcriptomic
Read More
Written by Pranav Kumar Patel
Published in Vol 2 Issue 2, 2022
The PHERGain study showed that a response-adapted approach guided by [18F]FDG-PET imaging, focused on achieving pathological complete response (pCR), allowed safe omission of chemotherapy in select individuals with HER2-positive early-stage breast cancer treated with neoadjuvant dual HER2-targeted therapy (trastuzumab plus pertuzumab, or HP). Given the restricted access to [18F]FDG-PET in many centers, this investigation explored the potential of breast MRI as a substitute modality for monitorin
Read More
Written by Katya Ivanova Sokolova
Published in Vol 2 Issue 2, 2022
This phase Ib study evaluated the IGF-1/IGF-2-neutralizing antibody xentuzumab combined with abemaciclib, with or without endocrine therapy (ET), in patients with advanced or metastatic solid tumors, particularly hormone receptor (HR)-positive, HER2-negative breast cancer. In the initial dose-escalation phase (cohort A), patients with advanced solid tumors received increasing doses of xentuzumab combined with abemaciclib. Subsequent dose-finding phases (cohorts B–D) enrolled patients with advanc
Read More
Written by Manuel Jesus Castro
Published in Vol 2 Issue 2, 2022
Although a rapid decline in Ki67 after short-term preoperative endocrine therapy (ET) has been established as a prognostic and predictive marker in controlled studies, its reliability and usefulness in everyday oncology practice are still insufficiently defined. In this real-world analysis, we investigated early on-treatment Ki67 modulation after brief preoperative ET and explored its relationship with tumor biology—including intrinsic molecular subtype and risk of recurrence (ROR)—together with
Read More
Written by Andrei Nicolae Popescu
Published in Vol 2 Issue 2, 2022
Previous research from the ShortHER trial established the prognostic value of tumor-infiltrating lymphocytes (TILs) in patients with early-stage HER2-positive breast cancer. This study investigates the influence of body mass index (BMI) on the prognostic impact of TILs. The ShortHER trial compared 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy in 1253 patients with HER2-positive early breast cancer. BMI data at baseline were available for 1213 patients (excluding 34 und
Read More
Written by Rebecca Anne Wilson
Published in Vol 2 Issue 2, 2022
In situ cancer vaccines represent an emerging strategy in cancer immunotherapy; however, the local immunosuppressive microenvironment within tumors limits their immune activation and therapeutic efficacy. The CXCL12/CXCR4 axis is a critical mediator of this immunosuppressive environment. In this study, siCXCR4 (S) was employed as an "immune adjuvant" and co-delivered with hydroxycamptothecin (HCPT) to construct an in situ cancer nanovaccine (HCPT/S@CaP/HA) aimed at synergistically inhibiting the
Read More
Written by Johanna Christina Petersen
Published in Vol 2 Issue 2, 2022
Tumor-derived fucosylated exosomes (FUC-Exo) have emerged as critical contributors to cancer progression, yet the roles and mechanisms of exosomal fucosylated miRNAs in esophageal squamous cell carcinoma (ESCC) remain largely unexplored. By employing lentil lectin (LCA)-coated magnetic beads to isolate FUC-Exo, followed by small RNA sequencing and RT-qPCR, miR-6842-3p was identified as a novel biomarker for ESCC. Functional studies in vitro and in vivo demonstrated its oncogenic and pro-angiogen
Read More
